La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

RhoVac Bilan de santé

Santé financière contrôle des critères 4/6

RhoVac possède un total de capitaux propres de SEK12.8M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK33.0M et de SEK20.2M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 9.92m
Fonds propres	SEK 12.78m
Total du passif	SEK 20.21m
Total des actifs	SEK 33.00m

Mises à jour récentes de la santé financière

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de RHOVAC ( SEK33.0M ) dépassent ses passifs à court terme ( SEK20.2M ).

Passif à long terme: RHOVAC n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: RHOVAC est sans dette.

Réduire la dette: RHOVAC n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RHOVAC dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: RHOVAC dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 21.8 % chaque année

RhoVac Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines